国际新闻
Makers of GLP-1 drugs ordered to add warnings about rare eye condition that can lead to blindness
来源: feeds.bbci.co.uk · 发布于
The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.
The US Food and Drug Administration says Ozempic, Wegovy, and other weight-loss drugs must have labels about the condition, known as NAION.
相关报道
FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to s
World news | The Guardian ·
Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Acces
Business | The Guardian ·
Trump administration seeks to cut food aid for more than six million people
Trump’s proposal builds on earlier cuts to federal food aid programme used by more than 36 million low-income Americans.
Al Jazeera – Breaking News, World News and Video from Al Jazeera ·
Sales of tinned food and bottled water jump after 'Be Ready' campaign launch
Sales of essential goods such as hand sanitiser soar after the government called on households to be prepared for emergencies.
feeds.bbci.co.uk ·
FDA warns GLP-1 drugs may pose risk of rare condition that causes vision loss
The Food and Drug Administration is warning that popular obesity drugs—including Ozempic, Wegovy, Zepbound, and Mounjaro—may carry a "potential increased risk" of a rare eye condition that can lead to permanent vision loss. In a drug safety communication Monday , the FDA said it
Ars Technica - All content ·